Kumamoto Health Science University

www.kumamoto-hsu.ac.jp
Kumamoto-shi, Japan

Kumamoto Health Science University is a private university in Kumamoto, Kumamoto, Japan, established in 2003. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Yano M.,Kumamoto Health Science University
Biochemical and Biophysical Research Communications | Year: 2017

Mitochondria have many functions, including ATP generation. The electron transport chain (ETC) and the coupled ATP synthase generate ATP by consuming oxygen. Reactive oxygen species (ROS) are also produced by ETC, and ROS damage deoxyribonucleic acids, membrane lipids and proteins. Recent analysis indicate that mitochondrial unfolded protein response (UPRmt), which enhances expression of mitochondrial chaperones and proteases to remove damaged proteins, is activated when damaged proteins accumulate in the mitochondria. In Caenorhabditis elegans, HAF-1, a putative ortholog of human ABCB10, plays an essential role in signal transduction from mitochondria to nuclei to enhance UPRmt. Therefore, it is possible that ABCB10 has a role similar to that of HAF-1. However, it has not been reported whether ABCB10 is a factor in the signal transduction pathway to enhance UPRmt. In this study, ABCB10 was depleted in HepG2 cells using small interfering RNA (siRNA), and the effect was examined. ABCB10 depletion upregulated ROS and the expression of ROS-detoxifying enzymes (SOD2, GSTA1, and GSTA2), and SESN3, a protein induced by ROS to protect the cell from oxidative stress. In addition, ABCB10 depletion significantly decreased expression of UPRmt-related mitochondrial chaperones (HSPD1 and DNAJA3), and a mitochondrial protease (LONP1). However, the putative activity of ABCB10 to export peptides from mitochondria was not lost by ABCB10 depletion. Altogether, these data suggest that ABCB10 is involved in UPRmt signaling pathway similar to that of HAF-1, although ABCB10 probably does not participate in peptide export from mitochondria. © 2017 Elsevier Inc.


Patent
Kyowa Medex Co. and Kumamoto Health Science University | Date: 2014-01-22

The present invention provides a method for simply and precisely measuring cholesterol in an HDL subfraction contained in a sample. This is a method for measuring cholesterol in HDL3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than HDL3.


Patent
Kumamoto Health Science University and Kyowa Medex Co. | Date: 2012-03-15

The present invention provides a method for simply and precisely measuring cholesterol in an HDL subfraction contained in a sample. This is a method for measuring cholesterol in HDL3 contained in a sample, which comprises reacting a sample with (1) a combination of a cholesterol ester hydrolase and a cholesterol oxidase or (2) a combination of a cholesterol ester hydrolase, an oxidized coenzyme and a cholesterol dehydrogenase in an aqueous medium containing: (a) a divalent metal salt; (b) an alkali metal salt selected from the group consisting of a sulfate, a nitrate, a carbonate, an acetate and a halide; and (c) dextran sulfate or a salt thereof, and measuring a substance formed or consumed in the reaction without separating and removing lipoproteins other than HDL3.


Kojima K.,Kyushu University | Takenaga K.,Kumamoto Health Science University | Yamashita T.,Nagoya University
Physical Review D - Particles, Fields, Gravitation and Cosmology | Year: 2011

We propose a novel way to break grand unified gauge symmetries via the Hosotani mechanism in models that can accommodate chiral fermions. Adjoint scalar fields are realized through the so-called diagonal embedding method which is often used in the heterotic string theory. We calculate the one-loop effective potential of the adjoint scalar field in a five dimensional model compactified on an S1/Z2 orbifold, as an illustration. It turns out that the potential is basically the same as the one in an S1 model, and thus the results in literatures, in addition to the chiral fermions, can be realized easily. © 2011 American Physical Society.


Patent
The Chemo Sero Therapeutic Research Institute, Kumamoto University and Kumamoto Health Science University | Date: 2012-06-13

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as FXIa), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.


Patent
Kumamoto University and Kumamoto Health Science University | Date: 2014-03-28

An object of the present invention is to provide a novel therapeutic agent for a patient with type 2 diabetes, a cause of which is the abnormal synthesis of insulin attributed to the abnormal modification of tRNA^(Lys )(UUU) in pancreatic cells having Cdkal1 gene mutation. The present inventors have used (1) a screening system using E. coli in which correct translation into luciferase requires frameshift resulting from mistranslation during protein translation, (2) a screening system using the pancreatic islet of Langerhans isolated from a pancreatic cell-specific Cdkal1-deficient mouse, and (3) a screening system using a pancreatic cell-specific Cdkal1-deficient mouse, and found that a compound represented by any of the following formulas (I) to (III) can serve as a therapeutic agent for a patient with type 2 diabetes with Cdkal1 gene mutation resulting in the reduced ability to secrete insulin.


Patent
Pharma Ip General Incorporated Association, Pharma Design Inc., Shizuoka Prefecture, Kumamoto Health Science University and Kabushiki Kaisha Yakult Honsha | Date: 2011-05-25

The present invention provides a STAT3 inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR^(34); and R^(1) to R^(8) and R^(34) each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof.


Patent
The Chemo Sero Therapeutic Research Institute, Kumamoto University and Kumamoto Health Science University | Date: 2010-08-05

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as FXIa), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.


Patent
General Incorporated Association Pharma Valley Project Supporting Organization, Pharma Design Inc., Kabushiki Kaisha Yakult Honsha, Kumamoto Health Science University and Shizuoka Prefecture | Date: 2010-12-28

Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R^(1 )represents a hydrogen atom or the like; and XY represents a diaryl group such as a biphenyl group).


Patent
General Incorporated Association Pharma Valley Project Supporting Organisation, Pharma Design Inc., Shizuoka Prefecture, Kumamoto Health Science University and Kabushiki Kaisha Yakult Honsha | Date: 2012-11-07

Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R^(1) represents a hydrogen atom or the like; and -X-Y represents a diaryl group such as a biphenyl group).

Loading Kumamoto Health Science University collaborators
Loading Kumamoto Health Science University collaborators